Mereo BioPharma Group plc (MREO)
After hours:
| Previous close | 4.0800 |
| Open | 4.1600 |
| Bid | 4.1400 x 300 |
| Ask | 4.1700 x 200 |
| Day's range | 3.9600 - 4.1700 |
| 52-week range | 1.0700 - 4.5000 |
| Volume | |
| Avg. volume | 1,078,445 |
| Market cap | 634.901M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings date | 05 Sept 2024 - 09 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.17 |
- Investing.com
Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week.
Globe NewswireMereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting
ZacksUltragenyx (RARE) Posts New Data From Bone Disease Study
Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.
